During an oral Spotlight Presentation, Codexis unveiled the successful end-to-end enzymatic synthesis of an entire approved siRNA therapeutic asset, inclisiran. Codexis enzymatically synthesized the ...

New all-in-one IVT kit can deliver up to 2X more mRNA and up to 85% lower dsRNA compared to other kits on the market through streamlined mRNA synthesis with efficient capping, increased yield, reduced ...

REDWOOD CITY, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has successfully synthesized an oligonucleotide via an ...

Researchers in the Pirbright Institute, UK, have experimentally proved that virus-related double-stranded RNA (dsRNA) and the sites of viral RNA synthesis are associated with one another. In addition, ...

Core enzymes for ECO Synthesis(TM) technology have transitioned from research into development and scale-up as the first step in securing the raw materials supply chain REDWOOD CITY, Calif., March 24, ...

TriLink’s CleanCap® AG (3’ OMe) CleanScript™ IVT Kit provides essential components for mRNA synthesis using co-transcriptional capping by in vitro transcription (IVT). The kit components are ...

REDWOOD CITY, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced data from ...

The new in vitro transcription (IVT) kit will simplify mRNA synthesis and elevate IVT by leveraging TriLink’s high-performing products where users can expect up to 2X more mRNA yield and up to 85% ...